Alpha medopa en es it fr

Alpha medopa Brand names, Alpha medopa Analogs

Alpha medopa Brand Names Mixture

  • No information avaliable

Alpha medopa Chemical_Formula


Alpha medopa RX_link

Alpha medopa fda sheet

Alpha_medopa FDA

Alpha medopa msds (material safety sheet)

Alpha_medopa MSDS

Alpha medopa Synthesis Reference

No information avaliable

Alpha medopa Molecular Weight

1270.28 g/mol

Alpha medopa Melting Point

No information avaliable

Alpha medopa H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Alpha medopa State


Alpha medopa LogP

No information avaliable

Alpha medopa Dosage Forms

Powder for solution (for injection)

Alpha medopa Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Alpha medopa Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Alpha medopa Absorption

No information avaliable

Alpha medopa side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Alpha medopa Patient Information

No information avaliable

Alpha medopa Organisms Affected

Aspergillis, Candida and other fungi